125 related articles for article (PubMed ID: 23171734)
1. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma.
Lin YL; Li ZG; Guan TY
Urol Int; 2013; 90(2):219-24. PubMed ID: 23171734
[TBL] [Abstract][Full Text] [Related]
2. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG
J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.
Deng J; Liang H; Ying G; Dong Q; Zhang L; Yu J; Fan D; Hao X
J Am Coll Surg; 2014 Nov; 219(5):904-13. PubMed ID: 25260683
[TBL] [Abstract][Full Text] [Related]
4. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
Yu J; Cheng YY; Tao Q; Cheung KF; Lam CN; Geng H; Tian LW; Wong YP; Tong JH; Ying JM; Jin H; To KF; Chan FK; Sung JJ
Gastroenterology; 2009 Feb; 136(2):640-51.e1. PubMed ID: 19084528
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.
Ma JG; He ZK; Ma JH; Li WP; Sun G
J Int Med Res; 2013 Feb; 41(1):38-47. PubMed ID: 23569128
[TBL] [Abstract][Full Text] [Related]
6. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
9. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.
Lin YL; Li ZG; He ZK; Guan TY; Ma JG
J Int Med Res; 2012; 40(6):2117-23. PubMed ID: 23321168
[TBL] [Abstract][Full Text] [Related]
11. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.
Lin YL; Liu XQ; Li WP; Sun G; Zhang CT
Int Urol Nephrol; 2012 Feb; 44(1):111-7. PubMed ID: 21516472
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
Catto JW; Azzouzi AR; Rehman I; Feeley KM; Cross SS; Amira N; Fromont G; Sibony M; Cussenot O; Meuth M; Hamdy FC
J Clin Oncol; 2005 May; 23(13):2903-10. PubMed ID: 15753461
[TBL] [Abstract][Full Text] [Related]
15. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
16. Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder.
Xuan Y; Kim S; Lin Z
J Cancer Res Clin Oncol; 2011 Jan; 137(1):49-54. PubMed ID: 20217126
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
18. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
19. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the polycomb group target gene PCDH7 in bladder tumors from patients of all ages.
Beukers W; Hercegovac A; Vermeij M; Kandimalla R; Blok AC; van der Aa MM; Zwarthoff EC; Zuiverloon TC
J Urol; 2013 Jul; 190(1):311-6. PubMed ID: 23369722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
